Replicel Life Sciences Stock Performance
| REPCF Stock | USD 0 0 950.00% |
RepliCel Life holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of 6.49, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RepliCel Life will likely underperform. Use RepliCel Life skewness, as well as the relationship between the rate of daily change and price action indicator , to analyze future returns on RepliCel Life.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in RepliCel Life Sciences are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental indicators, RepliCel Life reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 34.4 K |
RepliCel |
RepliCel Life Relative Risk vs. Return Landscape
If you would invest 4.30 in RepliCel Life Sciences on September 2, 2024 and sell it today you would lose (4.09) from holding RepliCel Life Sciences or give up 95.12% of portfolio value over 90 days. RepliCel Life Sciences is currently producing 19.5678% returns and takes up 135.9648% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than RepliCel, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
RepliCel Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RepliCel Life's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as RepliCel Life Sciences, and traders can use it to determine the average amount a RepliCel Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1439
| Best Portfolio | Best Equity | REPCF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 135.96 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average RepliCel Life is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RepliCel Life by adding it to a well-diversified portfolio.
RepliCel Life Fundamentals Growth
RepliCel Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of RepliCel Life, and RepliCel Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RepliCel Pink Sheet performance.
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| EBITDA | (4.07 M) | |||
| Cash And Equivalents | 228 K | |||
| Total Debt | 34.26 K | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (2.51 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 591.79 K | |||
| Retained Earnings | (14.76 M) | |||
About RepliCel Life Performance
By analyzing RepliCel Life's fundamental ratios, stakeholders can gain valuable insights into RepliCel Life's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if RepliCel Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if RepliCel Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. Replicel Life operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about RepliCel Life Sciences performance evaluation
Checking the ongoing alerts about RepliCel Life for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for RepliCel Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RepliCel Life is way too risky over 90 days horizon | |
| RepliCel Life has some characteristics of a very speculative penny stock | |
| RepliCel Life appears to be risky and price may revert if volatility continues | |
| RepliCel Life Sciences has accumulated 34.26 K in total debt. RepliCel Life Sciences has a current ratio of 0.23, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist RepliCel Life until it has trouble settling it off, either with new capital or with free cash flow. So, RepliCel Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RepliCel Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RepliCel to invest in growth at high rates of return. When we think about RepliCel Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 353.74 K. Net Loss for the year was (4.07 M) with profit before overhead, payroll, taxes, and interest of 353.74 K. | |
| RepliCel Life Sciences has accumulated about 228 K in cash with (2.51 M) of positive cash flow from operations. | |
| Roughly 68.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RepliCel Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RepliCel Life's stock is overvalued or undervalued compared to its peers.
- Examining RepliCel Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RepliCel Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RepliCel Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RepliCel Life's pink sheet. These opinions can provide insight into RepliCel Life's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for RepliCel Pink Sheet analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |